United BioPharma Receives TFDA Approval for Phase 2 IND for UB-221 to Treat Chronic Spontaneous Urticaria ...Middle East

TAIPEI, May 29, 2022 /PRNewswire/ -- Taiwan-based United BioPharma (UBP) has announced the approval of a Phase 2 clinical trial with novel anti-IgE monoclonal antibody UB-221 by the Taiwan Food and Drug Administration (TFDA). This Phase 2 clinical trial (double-blind, placebo-controlled)...

Hence then, the article about united biopharma receives tfda approval for phase 2 ind for ub 221 to treat chronic spontaneous urticaria was published today ( Monday 30/05/2022 - 06:08 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( United BioPharma Receives TFDA Approval for Phase 2 IND for UB-221 to Treat Chronic Spontaneous Urticaria )

Also on site :

• Timothee Chalamet Shows Subtle Support for Girlfriend Kylie Jenner
• From collapse fears to resilience: How Russia reshaped its economy by the end of 2025
• Russian MOD shows map of Ukrainian drone attack on Putin’s residence